New vaccines for neglected parasitic diseases and dengue (Q38098308)

28 August 2017

New vaccines for neglected parasitic diseases and dengue (English)

1 reference

28 August 2017

0 references

3

1 reference

28 August 2017

4

Maria Elena Bottazzi

1 reference

28 August 2017

1

Coreen M Beaumier

1 reference

28 August 2017

2

Portia M Gillespie

1 reference

28 August 2017

8 April 2013

1 reference

28 August 2017

Translational Research

1 reference

28 August 2017

162

1 reference

28 August 2017

144-155

1 reference

28 August 2017

3

1 reference

The Four Horsemen of the Apocalypse: Tropical Medicine in the Fight against Plague, Death, Famine, and War.

28 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Multivalent anthelminthic vaccine to prevent hookworm and schistosomiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Rescuing the bottom billion through control of neglected tropical diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Empowering women and improving female reproductive health through control of neglected tropical diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Examining the relationship between urogenital schistosomiasis and HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

A handful of 'antipoverty' vaccines exist for neglected diseases, but the world's poorest billion people need more

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Early clinical and laboratory indicators of acute dengue illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Human T cell responses to dengue virus antigens. Proliferative responses and interferon gamma production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Dengue virus-specific human T cell clones. Serotype crossreactive proliferation, interferon gamma production, and cytotoxic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Vaccines for the prevention of dengue: development update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Developing vaccines to combat hookworm infection and intestinal schistosomiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Relationship between intensity of soil-transmitted helminth infections and anemia during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Iron deficiency: global prevalence and consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Epidemiology of plasmodium-helminth co-infection in Africa: populations at risk, potential impact on anemia, and prospects for combining control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Rate of reinfection with intestinal nematodes after treatment of children with mebendazole or albendazole in a highly endemic area.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

The Human Hookworm Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Vaccine Development Against Leishmania donovani

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

The development and clinical evaluation of second-generation leishmaniasis vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Vaccine candidates for leishmaniasis: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Optimized subunit vaccine protects against experimental leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Parasites and poverty: the case of schistosomiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Novel immunomic technologies for schistosome vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Modeling the economic value of a Chagas' disease therapeutic vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Advances and challenges towards a vaccine against Chagas disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Impairment of infectivity and immunoprotective effect of a LYT1 null mutant of Trypanosoma cruzi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Future directions for vaccine-related onchocerciasis research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Identification of potential vaccine and drug target candidates by expressed sequence tag analysis and immunoscreening of Onchocerca volvulus larval cDNA libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Towards a vaccine for onchocerciasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

inferred from DOI database lookup

7 January 2021

based on heuristic

Evidence That Maternal Dengue Antibodies Are Important in the Development of Dengue Hemorrhagic Fever in Infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2013.03.006

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TRSL.2013.03.006

1 reference

28 August 2017

1 reference

PubMed ID

23578479